Literature DB >> 27660695

Update on the treatment of type 2 diabetes mellitus.

Juan José Marín-Peñalver1, Iciar Martín-Timón1, Cristina Sevillano-Collantes1, Francisco Javier Del Cañizo-Gómez1.   

Abstract

To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifestyle changes. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on the characteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.

Entities:  

Keywords:  Future treatments; Injectable antidiabetic agents; Older people; Oral antidiabetic agents; Renal impairment; Treatment; Type 2 diabetes mellitus

Year:  2016        PMID: 27660695      PMCID: PMC5027002          DOI: 10.4239/wjd.v7.i17.354

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


  363 in total

1.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

2.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

3.  A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.

Authors:  Azim S Gangji; Tali Cukierman; Hertzel C Gerstein; Charles H Goldsmith; Catherine M Clase
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

Review 4.  Inadequate sleep as a contributor to obesity and type 2 diabetes.

Authors:  Jessica McNeil; Éric Doucet; Jean-Philippe Chaput
Journal:  Can J Diabetes       Date:  2013-04-23       Impact factor: 4.190

5.  Nutrition education improves metabolic outcomes among older adults with diabetes mellitus: results from a randomized controlled trial.

Authors:  Carla K Miller; Lesley Edwards; Grace Kissling; Laurel Sanville
Journal:  Prev Med       Date:  2002-02       Impact factor: 4.018

Review 6.  Repaglinide: a review of its use in type 2 diabetes mellitus.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

Review 7.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

8.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

Review 9.  Zinc transporters and zinc signaling: new insights into their role in type 2 diabetes.

Authors:  Stephen A Myers
Journal:  Int J Endocrinol       Date:  2015-04-23       Impact factor: 3.257

10.  New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Authors:  G B Bolli; M C Riddle; R M Bergenstal; M Ziemen; K Sestakauskas; H Goyeau; P D Home
Journal:  Diabetes Obes Metab       Date:  2015-02-12       Impact factor: 6.577

View more
  116 in total

Review 1.  Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes.

Authors:  Yasaman Ghorbani; Katherine J P Schwenger; Johane P Allard
Journal:  Eur J Nutr       Date:  2021-03-02       Impact factor: 5.614

2.  Anti-inflammatory Action of Metformin with Respect to CX3CL1/CX3CR1 Signaling in Human Placental Circulation in Normal-Glucose Versus High-Glucose Environments.

Authors:  D Szukiewicz; Grzegorz Szewczyk; Michal Pyzlak; Aleksandra Stangret; Michal Bachanek; Seweryn Trojanowski; Habib Alkhalayla; Jaroslaw Wejman
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

3.  Sitagliptin-Induced Arthralgias: A Case Report.

Authors:  Raven Jackson; Isabel Sbeiti; Gabrielle Vincent
Journal:  Clin Diabetes       Date:  2020-07

Review 4.  Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases.

Authors:  Vidul Goenka; Tanhai Borkar; Aska Desai; Raunak Kumar Das
Journal:  J Diabetes Metab Disord       Date:  2020-10-17

5.  Metformin Accelerates Glycolytic Lactate Production in Cultured Primary Cerebellar Granule Neurons.

Authors:  Eva-Maria Blumrich; Ralf Dringen
Journal:  Neurochem Res       Date:  2017-07-07       Impact factor: 3.996

6.  Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model.

Authors:  Giovanna Sociali; Mirko Magnone; Silvia Ravera; Patrizia Damonte; Tiziana Vigliarolo; Maria Von Holtey; Valerio G Vellone; Enrico Millo; Irene Caffa; Michele Cea; Marco Daniele Parenti; Alberto Del Rio; Maximilien Murone; Raul Mostoslavsky; Alessia Grozio; Alessio Nencioni; Santina Bruzzone
Journal:  FASEB J       Date:  2017-04-06       Impact factor: 5.191

7.  A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models.

Authors:  Navasona Krishnan; Konstantis F Konidaris; Gilles Gasser; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2017-12-07       Impact factor: 5.157

8.  Hypertension, but not body mass index, is predictive of increased pancreatic lipid content and islet dysfunction.

Authors:  Daniel M Tremmel; Austin K Feeney; Samantha A Mitchell; Peter J Chlebeck; Sierra A Raglin; Luis A Fernandez; Jon S Odorico; Sara D Sackett
Journal:  Am J Transplant       Date:  2019-12-16       Impact factor: 8.086

9.  Nanoparticles of Antroquinonol-Rich Extract from Solid-State-Cultured Antrodia cinnamomea Improve Reproductive Function in Diabetic Male Rats.

Authors:  Zwe-Ling Kong; Jia-Ling He; Sabri Sudirman; Mao-Tien Kuo; Song Miao; Ke-Liang B Chang; David Tsou
Journal:  Int J Nanomedicine       Date:  2020-06-15

10.  Anti-atherosclerotic effects between a combined treatment with simvastatin plus hirudin and single simvastatin therapy in patients with early type 2 diabetes mellitus.

Authors:  De-Qiang Li; Fei-Fei Lv; Zhong-Chun Li; Zhi-Yuan Dai; Hong-Xia Wang; Yang Han
Journal:  Ann Transl Med       Date:  2019-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.